Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
China Pharmacy ; (12): 739-743, 2024.
Artigo em Chinês | WPRIM | ID: wpr-1013112

RESUMO

OBJECTIVE To provide reference for safe drug use in clinic by mining the adverse drug events (ADE) of 3 kinds of anti-influenza A virus drugs (oseltamivir, zanamivir, baloxavir marboxil). METHODS The ADE data of oseltamivir, zanamivir and baloxavir marboxil were collected from the FDA adverse event reporting system (FAERS) between the first quarter in 2004 and the third quarter in 2022, and mined by using reporting odds ratio (ROR) method. The designated medical events (DME) were estimated. The system organ class (SOC) in the Medical Dictionary for Regulatory Activities (MedDRA, version 25.0) was used for the classification and statistics of drug ADE terminology. RESULTS A total of 12 636, 1 749 and 1 283 ADE reports were retrieved for oseltamivir, zanamivir and baloxavir marboxil, involving 26, 16 and 17 SOCs, respectively. Oseltamivir was strongly associated with sleep terror, abnormal behavior, hallucination and delirium. Zanamivir was implicated in abnormal behavior, delirium, incoherence, and altered state of consciousness with prominent signal intensity. Baloxavir marboxil was strongly associated with ischemic colitis, hemorrhagic cystitis, erythema multiforme and melaena. Erythema multiform was detected in the DME of three drugs with strong signals. CONCLUSIONS When clinically administering the three drugs, it is crucial to pay close attention to both common adverse reactions and those ADEs that are not explicitly mentioned in the drug instructions. For oseltamivir, clinicians should exercise caution due to the potential risk of acute kidney injury and fulminant hepatitis, necessitating regular monitoring of the patient’s liver and kidney function. When prescribing zanamivir, caution should be exercised due to ADEs related to the respiratory system, including acute respiratory distress syndrome and respiratory failure, necessitating close monitoring of the patient’s respiratory status. Similarly, for baloxavir marboxil, clinicians should be vigilant for potential ADEs such as erythema multiforme and rhabdomyolysis.

2.
China Pharmacy ; (12): 868-871, 2023.
Artigo em Chinês | WPRIM | ID: wpr-969587

RESUMO

OBJECTIVE To mine adverse drug event (ADE) signals related to baloxavir marboxil, and to provide reference for clinically safe drug use. METHODS The ADE signals related to baloxavir marboxil from January 1, 2018 to May 31, 2022 in the US FDA adverse event reporting system (FAERS) were mined using the proportional reporting odds ratio (PRR) method. ADE with report number≥3, PRR≥2 and χ2≥4 was defined as a positive signal, and PRR method was used to analyze the ADE signal. RESULTS A total of 1 424 ADE reports with baloxavir marboxil as the main suspected drug were collected, involving 460 ADE signals. The femininity and patient under 18 years old were reported more, the country with the highest number of reports was the United States, and the main indication of drug reported was influenza. A total of 37 ADE positive signals were obtained after PRR calculation and screening exclusion, the first three ADE signals in the list of the reported number were diarrhea, vomiting and immediate hypersensitivity, and the first three ADE signals in the list of PRR value were febrile delirium, ischaemic colitis and hemorrhagic cystitis. Compared with the instructions of baloxavir marboxil, 18 ADE signals had not yet been included, such as abnormal liver function, hematuria, hemorrhagic cystitis, etc. Five new SOCs were involved, such as kidney and urinary system diseases, hepatobiliary system diseases, investigations, nervous system disorders and musculoskeletal and connective tissue disorders. CONCLUSIONS When clinical application of baloxavir marboxil, in addition to the adverse drug reactions mentioned in the drug instructions, attention should be paid to abnormal liver function, hematuria, hemorrhagic cystitis, etc, so as to guarantee the safety of drug use.

3.
China Pharmacy ; (12): 2402-2408, 2023.
Artigo em Chinês | WPRIM | ID: wpr-996399

RESUMO

OBJECTIVE To evaluate the effectiveness, safety and economy of baloxavir marboxil in the treatment of influenza, and to provide evidence-based reference for the introduction of new drugs in hospitals and clinical medication decisions. METHODS Retrieved from PubMed, Embase, Web of Science, Cochrane Library, Epistemonikos, CBM, CNKI, VIP, Wanfang database, official websites and relevant databases of health technology assessment (HTA) institutions, the results of the included studies were descriptively analyzed after literature screening, data extraction and quality evaluation. RESULTS A total of 11 studies were included, involving 6 systematic reviews/meta-analyses and 5 pharmacoeconomic studies. Compared with placebo, baloxavir marboxil significantly shortened the time to alleviation of symptoms (TTAS) and time to resolution of fever (TTRF), reduced the virus titer change from baseline at 24 h and 48 h after treatment and the incidence of bronchitis, with statistical significance (P< 0.05). Compared with neuraminidase inhibitors (NAIs), there were no significant differences in shortening TTRF and reducing the incidence of complications, pneumonia and bronchitis (P>0.05). The majority of studies suggested that there were no significant differences in shortening TTAS (P>0.05). Only very low-quality literature suggested that baloxavir marboxil could significantly reduce the virus titer change from baseline at 24 h and 48 h after treatment. In terms of safety, the incidences of adverse events (AEs) and drug-related adverse events (DRAEs) induced by baloxavir marboxil showed no significant differences, compared with peramivir and zanamivir (P>0.05). Some studies considered that the incidences of AEs and DRAEs with baloxavir marboxil were lower than placebo, oseltamivir and laninamivir. Compared with oseltamivir in China and laninamivir in Japan, baloxavir marboxil showed cost-effectiveness advantages. CONCLUSIONS Compared with placebo, baloxavir marboxil has good efficacy, safety and economy. Compared with NAIs (oseltamivir), baloxavir marboxil has good economic advantages in China, but further high-quality studies are still needed regarding its safety and efficacy.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA